Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
about
Observations following discontinuation of long-term denosumab therapy.UK clinical guideline for the prevention and treatment of osteoporosisRecent advances in the management of osteoporosisDenosumab: targeting the RANKL pathway to treat rheumatoid arthritis.Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study.Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOGDenosumab: an Emerging Therapy in Pediatric Bone Disorders.Clinical Features of 24 Patients With Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: Systematic Review and Additional Cases.Parathyroid Hormone and Parathyroid Hormone-Related Protein Analogs in Osteoporosis Therapy.Autophagy Maintains the Function of Bone Marrow Mesenchymal Stem Cells to Prevent Estrogen Deficiency-Induced Osteoporosis.Monoclonal antibodies for treating osteoporosis.Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates.Bone Loss After Denosumab: Only Partial Protection with Zoledronate.Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study.Multiple Vertebral Osteonecroses (Kümmell's Disease) After 10 Years on Denosumab: Is Osteocyte Apoptosis to Blame?Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension.Clinical vertebral fractures following denosumab discontinuation.Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis TherapyNew and emerging concepts in the use of denosumab for the treatment of osteoporosisAdvances and Unmet Needs in the Therapeutics of Bone Fragility
P2860
Q33563846-8B931CEF-6FE0-47CE-9FFA-E7F02207EA86Q33581078-F7C4E60D-9E31-47F0-902C-DA98C9E817F8Q33672136-9811F239-0DD5-4A4C-9D1E-8BEA4A56A231Q34545263-8ACA67CD-E450-438D-BB66-03BB9C0A5FEDQ36400219-2FE2862D-87D7-4B99-A5AF-8A69C3B45806Q36408112-372E8BEA-7178-4695-96F4-357298C16E3AQ37742180-8CEEB467-8C3C-4A07-B093-AB502444FA47Q38712724-5C7A88B7-72AE-4A57-9FDB-F9B5C335D4CEQ39152367-63C71CF1-2AF2-43F4-860B-9274CB2EF2BCQ39183207-1324AF69-2251-490B-95D1-61F25EB3B98CQ47154773-D7D33F5B-EA96-4D90-B63B-DEC71579090FQ47638169-8C78165B-5F4E-471E-8A5E-4C8459BDA82EQ48105410-EF522F4D-63A7-4345-B9EE-CDB85D49BE78Q48149601-B0DDBBCB-E51A-4FCF-A44D-A6DC96262066Q48249336-0AC483C4-142F-4BCB-9442-70BF9108DC14Q48365103-21A4B3A6-8D9A-4102-859E-22D2A3B7CE57Q50142958-B7FB34ED-28A9-46C6-8CF7-7794C68A03B9Q51653738-390A82E1-F6E7-4A9F-A7B5-D8FEF86E71E1Q57147876-E53F7A5A-EB5C-4081-9213-CF5101CFF832Q58583955-8A2CF13E-3170-4F5C-92D6-BA26F5481E7DQ58761409-E7C72960-D655-4DD1-A12C-05EA2E633304
P2860
Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Rebound-associated vertebral f ...... -from clinic and biomechanics.
@en
Rebound-associated vertebral f ...... -from clinic and biomechanics.
@nl
type
label
Rebound-associated vertebral f ...... -from clinic and biomechanics.
@en
Rebound-associated vertebral f ...... -from clinic and biomechanics.
@nl
prefLabel
Rebound-associated vertebral f ...... -from clinic and biomechanics.
@en
Rebound-associated vertebral f ...... -from clinic and biomechanics.
@nl
P2860
P50
P1476
Rebound-associated vertebral f ...... b-from clinic and biomechanics
@en
P2093
P K Zysset
P2860
P2888
P304
P356
10.1007/S00198-015-3458-6
P407
P577
2015-12-22T00:00:00Z